Find your next paid study

Bien-Willner Physicians Group PANCT06090513

~$10 – $1,125

Hematologic MalignancyBlood CancerLymphoma+2 more

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy: The PEACE Study

The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymp…

Massachusetts General HospitalNCT05646576

Bladder CancerMuscle-Invasive Bladder CarcinomaUrothelial Carcinoma+3 more

Randomized Controlled Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

Subjects will be randomized into 2 groups (stent or no stent) prior to radical cystectomy with ileal conduit urinary diversion (RCIC). They will follow the sta…

Thomas Jefferson UniversityNCT07234968

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

To learn if the combination of atezolizumab and tiragolumab can help to control bladder cancer when it is given before surgery to remove the bladder and tumor.

Metastatic Malignancy

M.D. Anderson Cancer CenterNCT05394337

Mechanisms of Disease Relapse/Resistance in CAR T Therapy for Hematologic Malignancies

The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in pa…

Hematologic Malignancy

Duke UniversityNCT05397132

~$10 – $750

A Phase II Trial of Reduced Intensity Fludarabine and Total Body Irradiation-Based Conditioning Prior to Haplo-Identical Transplantation for Patients With Hematologic Malignancies

This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the …

Hematologic Malignancy

Northside Hospital, Inc.NCT05417971

~$10 – $750

MalignancyImmune Related Adverse Events

A Non-Interventional Pragmatic Clinical Trial of NLP Models for the Detection of Immune-Related Adverse Events

Immunotherapies have improved cancer outcomes, but have a unique profile of immune-related adverse events (irAEs). Biorepositories have been established to col…

Brigham and Women's HospitalNCT06789601

Phase 2

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be w…

Myeloid Malignancy

Henry Ford Health SystemNCT03850418

Hematologic MalignancyALL, ChildhoodAML, Childhood+2 more

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-…

St. Jude Children's Research HospitalNCT06326463

Lymphatic DiseasesHematopoietic Malignancy

Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

For the next 5-10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB) inventory worldwide will be composed of unlicensed umbilical cord b…

Masonic Cancer Center, University of MinnesotaNCT01451502

Hematologic MalignancyAMLALL+8 more

A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult pati…

Therapeutic Advances in Childhood Leukemia ConsortiumNCT05476770

~$10 – $7,500

Hematologic CancerHematologic Malignancy

Reducing Persistent Fatigue Following Hematopoietic Stem Cell Transplantation

The purpose of this study is to assess whether a cognitive-behavioral therapy (CBT) for fatigue intervention is acceptable, feasible, and effective at managing…